Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCTGlobeNewsWire • 05/16/22
Cellectis S.A.'s (CLLS) CEO Andre Choulika on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022GlobeNewsWire • 05/12/22
Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial ResultsGlobeNewsWire • 05/05/22
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia TherapeuticsGlobeNewsWire • 04/27/22
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual MeetingGlobeNewsWire • 04/08/22
Cellectis S.A. (CLLS) CEO Andre Choulika on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/04/22
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/03/22
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM ESTGlobeNewsWire • 02/24/22
Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Factor DisclosureGlobeNewsWire • 02/18/22
Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical TrialsGlobeNewsWire • 01/10/22
Cellectis Provides Business Objectives for 2022 and Updates its Corporate PresentationGlobeNewsWire • 01/04/22
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual MeetingGlobeNewsWire • 12/11/21
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in ChinaGlobeNewsWire • 11/18/21
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of CancerGlobeNewsWire • 11/12/21
Cellectis S.A. (CLLS) CEO Andre Choulika on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021GlobeNewsWire • 11/04/21